New Zealand has a long history of cancer drug development dating back to the earliest cancer drugs. Cancer drug development encompasses a number of disciplines, and involves multiple technologies; for example, medicinal chemistry and synthetic organic chemical engineering and analysis, computer molecular modelling and molecular structural analysis, mathematics and statistical analysis, in vitro and in vivo cell growth and tumour xenograft studies, signal transduction pathway studies, CRISPR-Cas9 genome editing and molecular biological analysis, immune response, pharmacogenomics, bioinformatics and so on.
The next frontier is where molecular profiling can guide the development of individualized or personalized drug treatment of cancer patients. This kind of approach promises to revolutionize the field, and will open the door to precision cancer medicine. Listen to Dr Jeffrey Ross discuss the next frontier of cancer treatment.
Early Stage Laboratory Research and Pre-clinical Development of Cancer Drugs
Pharmaceutical Industry-sponsored Pre-clinical and Clinical Development of Cancer Drugs